Rhythm Pharmaceuticals Inc (NAS:RYTM)
$ 67.33 3.43 (5.37%) Market Cap: 4.14 Bil Enterprise Value: 3.63 Bil PE Ratio: 0 PB Ratio: 349.18 GF Score: 60/100

Rhythm Pharmaceuticals, Inc. - Special Call Transcript

Aug 07, 2019 / 12:00PM GMT
Release Date Price: $21.84 (+14.95%)
Operator

Good day, ladies and gentlemen, and welcome to the Rhythm Pharmaceuticals Conference Call. (Operator Instructions) Please be advised that the call is being recorded at the company's request.

At this time, I would like to turn the call over to David Connolly, Head of Investor Relations and Corporate Communications at Rhythm. Please proceed.

David Connolly
Rhythm Pharmaceuticals, Inc. - Head of IR & Corporate Communications

Thank you, and thank you to everyone for joining us today to review the top line results from our 2 pivotal Phase III studies of setmelanotide for the treatment of POMC deficiency obesity and LEPR deficiency obesity. Please note the press release issued earlier today and the presentation we're using for this conference call are available on the Investors & Media section of the Rhythm website.

On today's call are Dr. Keith Gottesdiener, Chief Executive Officer, Rhythm; and Dr. Murray Stewart, Chief Medical Officer, who will provide an overview of these data and what they mean for patients with rare genetic disorders

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot